Zuberitamab with bendamustine for untreated follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug (zuberitamab) combined with chemotherapy (bendamustine) for people with untreated follicular lymphoma. If you are newly diagnosed and have advanced-stage disease with symptoms, this treatment may help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with follicular lymphoma (grades 1-3a) that is CD20-positive.
- You have not had any prior treatment for this lymphoma.
- Your lymphoma is at an advanced stage (III or IV), or stage II with a large tumor (at least 7 cm).
- You have tumors that can be measured on scans and you have symptoms like fever, weight loss, or organ issues related to the lymphoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether three drugs (sonrotoclax, zanubrutinib, and rituximab) work together to treat follicular lymphoma in patients who have never received treatment before. The goal is to shrink tumors and improve survival.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (G-CVP) for people with follicular lymphoma who have not had treatment before. It aims to see if this combination is safe and effective.
This trial tests a new combination of three targeted drugs (Orelabrutinib, Obinutuzumab, and Lenalidomide) against the standard approach for people with follicular lymphoma who haven't been treated yet. The goal is to see if the new drug combo works better and is safe.
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (G-CHOP) in people with newly diagnosed, intermediate-high risk follicular lymphoma that has not yet been treated. The goal is to see if this combination works better than current standard treatments.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
Hear when a new Follicular Lymphoma (FL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.